 Elizabeth Kessler
Concepts (235)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urinary Bladder Neoplasms | 8 | 2026 | 258 | 2.890 |
Why?
| | Prostatic Neoplasms | 14 | 2025 | 981 | 2.840 |
Why?
| | Carcinoma, Renal Cell | 8 | 2023 | 230 | 1.870 |
Why?
| | Kidney Neoplasms | 10 | 2023 | 415 | 1.850 |
Why?
| | Suicide, Assisted | 6 | 2024 | 31 | 1.670 |
Why?
| | Antineoplastic Agents | 11 | 2026 | 2219 | 1.590 |
Why?
| | Prostate-Specific Antigen | 3 | 2021 | 161 | 1.240 |
Why?
| | Physicians | 6 | 2024 | 956 | 0.920 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 6 | 2026 | 1969 | 0.870 |
Why?
| | Oncologists | 2 | 2024 | 47 | 0.870 |
Why?
| | Patient Care Planning | 1 | 2026 | 170 | 0.850 |
Why?
| | Patient Preference | 1 | 2025 | 223 | 0.740 |
Why?
| | Prostatic Neoplasms, Castration-Resistant | 3 | 2026 | 53 | 0.730 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2018 | 1150 | 0.610 |
Why?
| | Orchiectomy | 3 | 2016 | 72 | 0.610 |
Why?
| | Anilides | 5 | 2023 | 84 | 0.600 |
Why?
| | Aged | 28 | 2026 | 26217 | 0.590 |
Why?
| | Euterpe | 1 | 2018 | 4 | 0.570 |
Why?
| | Abiraterone Acetate | 1 | 2017 | 15 | 0.500 |
Why?
| | Plant Extracts | 1 | 2018 | 188 | 0.490 |
Why?
| | Prednisone | 1 | 2017 | 226 | 0.460 |
Why?
| | Capecitabine | 1 | 2015 | 56 | 0.460 |
Why?
| | Indazoles | 2 | 2014 | 85 | 0.460 |
Why?
| | Biliary Tract Neoplasms | 1 | 2015 | 31 | 0.460 |
Why?
| | Pyridines | 5 | 2023 | 609 | 0.450 |
Why?
| | Frailty | 1 | 2018 | 205 | 0.440 |
Why?
| | Imidazoles | 2 | 2014 | 247 | 0.430 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2015 | 58 | 0.430 |
Why?
| | Humans | 57 | 2026 | 145783 | 0.420 |
Why?
| | Carcinoma, Papillary | 1 | 2015 | 82 | 0.420 |
Why?
| | Deoxycytidine | 1 | 2015 | 220 | 0.420 |
Why?
| | Spinal Neoplasms | 1 | 2014 | 37 | 0.420 |
Why?
| | Quinazolines | 1 | 2015 | 266 | 0.410 |
Why?
| | Piperidines | 1 | 2015 | 222 | 0.410 |
Why?
| | Neoplasms | 6 | 2023 | 2913 | 0.410 |
Why?
| | Testicular Neoplasms | 3 | 2023 | 111 | 0.400 |
Why?
| | Neoplasm Metastasis | 5 | 2020 | 688 | 0.390 |
Why?
| | Immunotherapy | 1 | 2018 | 668 | 0.380 |
Why?
| | Canada | 5 | 2023 | 432 | 0.340 |
Why?
| | Male | 31 | 2026 | 73011 | 0.340 |
Why?
| | Aged, 80 and over | 8 | 2026 | 8347 | 0.320 |
Why?
| | Geriatric Assessment | 4 | 2021 | 240 | 0.320 |
Why?
| | Protein Kinase Inhibitors | 2 | 2017 | 981 | 0.310 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2015 | 641 | 0.310 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 2 | 2023 | 76 | 0.290 |
Why?
| | Surveys and Questionnaires | 9 | 2025 | 6085 | 0.290 |
Why?
| | Adaptation, Psychological | 1 | 2014 | 719 | 0.290 |
Why?
| | Aging | 2 | 2018 | 1973 | 0.280 |
Why?
| | Androgen Antagonists | 3 | 2020 | 91 | 0.270 |
Why?
| | Age Factors | 4 | 2026 | 3346 | 0.260 |
Why?
| | Pancreatic Neoplasms | 1 | 2015 | 928 | 0.260 |
Why?
| | Palliative Care | 4 | 2026 | 1022 | 0.260 |
Why?
| | Middle Aged | 17 | 2026 | 36309 | 0.250 |
Why?
| | Neoplasm Staging | 5 | 2023 | 1475 | 0.250 |
Why?
| | Neoadjuvant Therapy | 2 | 2021 | 467 | 0.250 |
Why?
| | Caregivers | 2 | 2023 | 1074 | 0.250 |
Why?
| | Urothelium | 3 | 2019 | 33 | 0.250 |
Why?
| | Communication | 2 | 2024 | 977 | 0.240 |
Why?
| | Delphi Technique | 2 | 2026 | 333 | 0.240 |
Why?
| | Carcinoma, Transitional Cell | 2 | 2019 | 68 | 0.240 |
Why?
| | Neoplasm Invasiveness | 2 | 2020 | 508 | 0.240 |
Why?
| | Malignant Atrophic Papulosis | 1 | 2025 | 1 | 0.240 |
Why?
| | Treatment Outcome | 8 | 2025 | 11794 | 0.240 |
Why?
| | Carboplatin | 1 | 2026 | 164 | 0.230 |
Why?
| | Stress, Psychological | 1 | 2014 | 1151 | 0.230 |
Why?
| | Biopsy | 3 | 2025 | 1082 | 0.200 |
Why?
| | Penile Neoplasms | 1 | 2023 | 7 | 0.200 |
Why?
| | Subacute Care | 1 | 2024 | 84 | 0.190 |
Why?
| | Terminally Ill | 1 | 2023 | 40 | 0.190 |
Why?
| | Pilot Projects | 5 | 2023 | 1898 | 0.190 |
Why?
| | Molecular Targeted Therapy | 2 | 2018 | 441 | 0.180 |
Why?
| | Bone Neoplasms | 2 | 2015 | 265 | 0.180 |
Why?
| | Administration, Oral | 1 | 2025 | 867 | 0.180 |
Why?
| | Skilled Nursing Facilities | 1 | 2024 | 152 | 0.180 |
Why?
| | Quality of Life | 4 | 2022 | 3211 | 0.180 |
Why?
| | Female | 18 | 2025 | 79045 | 0.170 |
Why?
| | Adenosine Deaminase | 1 | 2021 | 43 | 0.170 |
Why?
| | Medical Oncology | 2 | 2021 | 340 | 0.170 |
Why?
| | Vasculitis | 1 | 2021 | 69 | 0.170 |
Why?
| | Cross-Sectional Studies | 3 | 2025 | 5925 | 0.170 |
Why?
| | Lung Neoplasms | 1 | 2014 | 2668 | 0.160 |
Why?
| | Skin | 1 | 2025 | 754 | 0.160 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2023 | 238 | 0.160 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2023 | 198 | 0.160 |
Why?
| | Videoconferencing | 1 | 2020 | 65 | 0.160 |
Why?
| | Ureteral Neoplasms | 1 | 2019 | 1 | 0.150 |
Why?
| | Nephroureterectomy | 1 | 2019 | 2 | 0.150 |
Why?
| | Adult | 11 | 2025 | 40881 | 0.150 |
Why?
| | Hospice Care | 1 | 2022 | 228 | 0.150 |
Why?
| | Physical Examination | 1 | 2020 | 244 | 0.150 |
Why?
| | Physician-Patient Relations | 1 | 2024 | 588 | 0.150 |
Why?
| | Rheumatology | 1 | 2020 | 133 | 0.140 |
Why?
| | Colorado | 3 | 2024 | 4556 | 0.140 |
Why?
| | Fruit and Vegetable Juices | 1 | 2018 | 22 | 0.140 |
Why?
| | United States | 6 | 2025 | 16126 | 0.140 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 2018 | 63 | 0.140 |
Why?
| | Patient Selection | 2 | 2020 | 739 | 0.130 |
Why?
| | Frail Elderly | 1 | 2018 | 136 | 0.130 |
Why?
| | Wilms Tumor | 1 | 2018 | 90 | 0.130 |
Why?
| | Attitude of Health Personnel | 3 | 2024 | 1197 | 0.130 |
Why?
| | Patient Discharge | 1 | 2024 | 995 | 0.130 |
Why?
| | Proton Therapy | 1 | 2017 | 15 | 0.130 |
Why?
| | Checklist | 1 | 2018 | 110 | 0.120 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2023 | 992 | 0.120 |
Why?
| | Prognosis | 4 | 2023 | 4330 | 0.120 |
Why?
| | Seminoma | 1 | 2017 | 20 | 0.120 |
Why?
| | Taxoids | 1 | 2017 | 114 | 0.120 |
Why?
| | Cancer Survivors | 1 | 2022 | 338 | 0.120 |
Why?
| | Cisplatin | 1 | 2018 | 345 | 0.120 |
Why?
| | Documentation | 1 | 2018 | 199 | 0.120 |
Why?
| | Nutritional Status | 1 | 2018 | 353 | 0.120 |
Why?
| | Mass Screening | 2 | 2021 | 1361 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 391 | 0.110 |
Why?
| | Receptor Protein-Tyrosine Kinases | 2 | 2021 | 231 | 0.110 |
Why?
| | Coronavirus Infections | 1 | 2020 | 384 | 0.110 |
Why?
| | Clinical Decision-Making | 1 | 2018 | 364 | 0.110 |
Why?
| | Radiation Tolerance | 1 | 2015 | 103 | 0.110 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2014 | 50 | 0.100 |
Why?
| | Muscle, Smooth | 1 | 2015 | 153 | 0.100 |
Why?
| | Decision Making | 1 | 2022 | 982 | 0.100 |
Why?
| | Patient Acceptance of Health Care | 1 | 2020 | 883 | 0.100 |
Why?
| | Neoplasms, Complex and Mixed | 1 | 2013 | 7 | 0.100 |
Why?
| | Demography | 1 | 2014 | 282 | 0.100 |
Why?
| | Carcinoma, Medullary | 1 | 2013 | 16 | 0.100 |
Why?
| | Lymphatic Metastasis | 1 | 2014 | 336 | 0.100 |
Why?
| | Risk Assessment | 2 | 2023 | 3752 | 0.090 |
Why?
| | Angiogenesis Inhibitors | 1 | 2014 | 239 | 0.090 |
Why?
| | Energy Metabolism | 1 | 2018 | 935 | 0.090 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2013 | 254 | 0.090 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2014 | 533 | 0.090 |
Why?
| | Feasibility Studies | 3 | 2023 | 1115 | 0.090 |
Why?
| | Pediatrics | 1 | 2020 | 1125 | 0.090 |
Why?
| | Bone Diseases | 1 | 2012 | 61 | 0.090 |
Why?
| | Radiography | 1 | 2014 | 853 | 0.090 |
Why?
| | Pandemics | 1 | 2020 | 1711 | 0.090 |
Why?
| | Clinical Competence | 1 | 2020 | 1247 | 0.090 |
Why?
| | Drugs, Investigational | 1 | 2011 | 31 | 0.090 |
Why?
| | Needs Assessment | 1 | 2014 | 403 | 0.090 |
Why?
| | Health Personnel | 1 | 2018 | 757 | 0.080 |
Why?
| | Radiosurgery | 1 | 2015 | 399 | 0.080 |
Why?
| | Urinary Bladder | 1 | 2013 | 196 | 0.080 |
Why?
| | Telemedicine | 1 | 2020 | 967 | 0.080 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2012 | 217 | 0.080 |
Why?
| | Sarcoma | 1 | 2013 | 207 | 0.080 |
Why?
| | Antibodies, Monoclonal | 1 | 2018 | 1505 | 0.080 |
Why?
| | Disease Progression | 1 | 2018 | 2865 | 0.080 |
Why?
| | Pyrimidines | 1 | 2014 | 530 | 0.080 |
Why?
| | Sulfonamides | 1 | 2014 | 583 | 0.080 |
Why?
| | Practice Guidelines as Topic | 1 | 2018 | 1582 | 0.080 |
Why?
| | Recombinant Fusion Proteins | 1 | 2012 | 666 | 0.080 |
Why?
| | Neoplasm Proteins | 1 | 2013 | 442 | 0.080 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2013 | 534 | 0.070 |
Why?
| | B7-H1 Antigen | 2 | 2022 | 244 | 0.070 |
Why?
| | Quality Improvement | 1 | 2018 | 1296 | 0.070 |
Why?
| | Survival Rate | 3 | 2019 | 2094 | 0.070 |
Why?
| | Survival Analysis | 2 | 2021 | 1378 | 0.060 |
Why?
| | Ataxia Telangiectasia Mutated Proteins | 1 | 2026 | 69 | 0.060 |
Why?
| | Isoxazoles | 1 | 2026 | 56 | 0.060 |
Why?
| | Pyrazines | 1 | 2026 | 94 | 0.060 |
Why?
| | Nephrectomy | 2 | 2018 | 163 | 0.060 |
Why?
| | Cohort Studies | 1 | 2015 | 6033 | 0.050 |
Why?
| | Conscience | 1 | 2024 | 9 | 0.050 |
Why?
| | Risk Factors | 1 | 2018 | 10919 | 0.050 |
Why?
| | Disclosure | 1 | 2023 | 84 | 0.050 |
Why?
| | Drug Interactions | 2 | 2017 | 405 | 0.050 |
Why?
| | Retrospective Studies | 4 | 2023 | 17330 | 0.050 |
Why?
| | Morals | 1 | 2023 | 79 | 0.050 |
Why?
| | Combined Modality Therapy | 1 | 2025 | 1271 | 0.050 |
Why?
| | Telephone | 1 | 2023 | 177 | 0.050 |
Why?
| | SEER Program | 1 | 2023 | 230 | 0.040 |
Why?
| | Young Adult | 4 | 2023 | 14254 | 0.040 |
Why?
| | Severe Combined Immunodeficiency | 1 | 2021 | 22 | 0.040 |
Why?
| | Agammaglobulinemia | 1 | 2021 | 36 | 0.040 |
Why?
| | Multicenter Studies as Topic | 1 | 2023 | 413 | 0.040 |
Why?
| | Adolescent | 4 | 2025 | 22577 | 0.040 |
Why?
| | Intention to Treat Analysis | 1 | 2021 | 79 | 0.040 |
Why?
| | Fatigue | 1 | 2023 | 366 | 0.040 |
Why?
| | Prostate | 1 | 2022 | 159 | 0.040 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2021 | 376 | 0.040 |
Why?
| | Follow-Up Studies | 2 | 2022 | 5428 | 0.040 |
Why?
| | Europe | 1 | 2020 | 421 | 0.040 |
Why?
| | Clinical Trials as Topic | 2 | 2016 | 1062 | 0.040 |
Why?
| | Hospitals | 1 | 2023 | 733 | 0.040 |
Why?
| | Neoplasm Grading | 1 | 2019 | 311 | 0.030 |
Why?
| | Central Nervous System | 1 | 2020 | 282 | 0.030 |
Why?
| | Survivors | 1 | 2022 | 523 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2019 | 770 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2019 | 782 | 0.030 |
Why?
| | Pain | 1 | 2023 | 791 | 0.030 |
Why?
| | Betacoronavirus | 1 | 2020 | 289 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2021 | 1330 | 0.030 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2017 | 54 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2023 | 1752 | 0.030 |
Why?
| | Endothelial Cells | 1 | 2021 | 878 | 0.030 |
Why?
| | Pregnancy Outcome | 1 | 2018 | 504 | 0.030 |
Why?
| | Cognition | 1 | 2023 | 1271 | 0.030 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 1 | 2015 | 149 | 0.030 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2015 | 142 | 0.030 |
Why?
| | Cytokines | 1 | 2021 | 2069 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 2 | 2018 | 3916 | 0.020 |
Why?
| | beta-Galactosidase | 1 | 2013 | 76 | 0.020 |
Why?
| | Delivery of Health Care | 1 | 2020 | 948 | 0.020 |
Why?
| | Breeding | 1 | 2013 | 63 | 0.020 |
Why?
| | Staining and Labeling | 1 | 2013 | 153 | 0.020 |
Why?
| | Hyperplasia | 1 | 2013 | 177 | 0.020 |
Why?
| | Tumor Stem Cell Assay | 1 | 2012 | 34 | 0.020 |
Why?
| | Keratins | 1 | 2013 | 171 | 0.020 |
Why?
| | Organ Specificity | 1 | 2013 | 309 | 0.020 |
Why?
| | Integrases | 1 | 2013 | 122 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2013 | 365 | 0.020 |
Why?
| | Adenoviridae | 1 | 2013 | 199 | 0.020 |
Why?
| | RNA, Untranslated | 1 | 2013 | 121 | 0.020 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2013 | 427 | 0.020 |
Why?
| | Animals | 4 | 2017 | 38102 | 0.020 |
Why?
| | Databases, Factual | 1 | 2017 | 1491 | 0.020 |
Why?
| | Mutation | 1 | 2021 | 4090 | 0.020 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2012 | 936 | 0.020 |
Why?
| | ErbB Receptors | 1 | 2012 | 635 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2013 | 1723 | 0.020 |
Why?
| | Genotype | 1 | 2013 | 1857 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2012 | 2028 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2018 | 2770 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2013 | 2191 | 0.020 |
Why?
| | Time Factors | 1 | 2019 | 7134 | 0.020 |
Why?
| | Practice Patterns, Physicians' | 1 | 2017 | 1372 | 0.020 |
Why?
| | Prospective Studies | 1 | 2019 | 8078 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2018 | 6465 | 0.020 |
Why?
| | Biomarkers, Tumor | 1 | 2013 | 1329 | 0.010 |
Why?
| | Pregnancy | 1 | 2018 | 7216 | 0.010 |
Why?
| | Mice | 2 | 2013 | 18356 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2013 | 3418 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2012 | 2514 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2012 | 3551 | 0.010 |
Why?
| | Child | 1 | 2023 | 22740 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2012 | 4568 | 0.010 |
Why?
|
|
Kessler's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|